Osteoarthritis Pain Drug Market (Drug Class - Corticosteriods, NSAIDS, Viscosupplementation, and Others; Route of Administration - Oral, Parenteral, and Topical; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025

  • Published : December, 2019

  • Rep Id : HC0776

  • Category : Healthcare & Medical Devices

  • Status : Published

A recent report published by Infinium Global Research on osteoarthritis pain drug market provides in-depth analysis of segments and sub-segments in the global as well as regional osteoarthritis pain drug market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional osteoarthritis pain drug market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global osteoarthritis pain drug market. According to the report, the global osteoarthritis pain drug market is projected to grow at a CAGR of 7.9% over the forecast period of 2019-2025.

 

Market Insight

Osteoarthritis, the most common type of arthritis, is a leading cause of disability. It is a chronic, progressive degenerative joint disease, which is characterized by the gradual destruction of the articular cartilage, hypertrophy of the bone margins, a series of biochemical and morphological changes in the synovial membrane and joint capsule. Currently, there is no cure to stop osteoarthritis pain but to reduce using different treatments or therapies. However, osteoarthritis pain drugs are used to relieve pain. The most commonly used drugs for osteoarthritis are aspirin, ibuprofen, naproxen, and celecoxib. Medicines for osteoarthritis pain are available as pills, syrups, creams, lotions and they are injected into a joint.

 

Osteoarthritis is growing as a major public health problem worldwide. The rapidly growing aging population is the primary factor for the growth in the number of people affected by osteoarthritis. The prevalence of osteoarthritis increased by 33% among those aged from 60 to 70 years to 43.7% among those over 80 years of age. According to the World Health Organization (WHO) report, Osteoarthritis disease is found more in females rather than males aged over 60 years. Thereby, increasing the demand for osteoarthritis drugs. Furthermore, a rise in R&D expenditure and increased geriatric population are other factors propelling the growth of osteoarthritis pain drugs market. Also, increased awareness regarding degenerative bone diseases in developing countries and a rich pipeline of innovative treatment options are the factors boosting the osteoarthritis pain drugs market. However, severe side effects associated with certain injectable treatments remain major restraints to the market. The treatment options available in the market fail to provide suitable pain relief in the late stages of osteoarthritis. This led to a larger number of people opting for natural treatments such as yoga, chiropractic, homeopathy, and naturopathy, to treat osteoarthritis. Moreover, several pharmaceutical companies are focusing on the new formulation of the drug for the treatment of osteoarthritis. Many clinical trials and researches are being performed in different phases and new drugs are expected to be launched in the market. This is anticipated to generate favorable opportunities for several manufacturers in the osteoarthritis pain drugs market.

 

Geographically, North America holds the dominant share in the osteoarthritis pain market. The availability of better treatment options, high awareness among people, government reimbursement policies is a major factor driving the osteoarthritis pain drug market in North America. Osteoarthritis is the most common joint disorder in the United States and affects over 30 million US adults. The Asia Pacific region holds the second largest market share in the osteoarthritis pain drug market. The Asia Pacific (APAC) region is aging more rapidly than any region. In addition, the old-age support ratio in China is projected to plummet from 7.9 to 2.4 by 2050 that in turn will facilitate demand for osteoarthritis drugs in the Asia Pacific region. Furthermore, Japan is the second-largest market for viscosupplementation products after the U.S. which in turn is anticipated to further boost the market in the Asia Pacific in the near future.

 

Segment Covered

The report on global osteoarthritis pain drug market covers segments such as drug class, route of administration, and distribution channel. On the basis of drug class, the sub-markets include corticosteroids, NSAIDS, viscosupplementation, and others. On the basis of the route of administration, the sub-markets include oral, parenteral, and topical. On the basis of the distribution channel, the sub-markets include hospital pharmacies, retail pharmacies, and online pharmacies.

 

Companies Profiled:

The report provides profiles of the companies in the market such as Horizon Pharma plc, Pfizer Inc, Sanofi S.A., Anika Therapeutics, Inc., Ferring B.V., Bioventus, Inc., Chugai Pharmaceutical Co., Limited, Alkem Laboratories, Flexion Therapeutics, Inc., and Zimmer Biomet Holdings, Inc.

 

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the osteoarthritis pain drug market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount